15
Apr 2026
Rural Nebraska dialysis unit closes despite the state’s $219M in rural health funding
The sun was just warming the horizon as Mark Pieper left his house near his cattle ranch on a crisp February morning.
STAY INFORMED!
15
Apr 2026
MAIA: Bringing AI into your sample preparation
Transform laboratory workflows with MAIA, the AI agent offering instant expert guidance for microwave digestion, ensuring optimal sample preparation.
15
Apr 2026
Metabolic syndrome doubles worldwide over two decades
A global study reveals a sharp rise in metabolic syndrome prevalence from 2000 to 2023, highlighting urgent public health challenges and regional disparities.
15
Apr 2026
ORGAPRED selects CYTOQUBE® from Hamamatsu Photonics for personalized oncology research and therapeutic discovery
ORGAPRED, a France-based core facility specializing in Patient-Derived Tumor Organoid (PDTO) research, has selected the CYTOQUBE high-throughput 3D imaging system from Hamamatsu Photonics France to support personalized oncology drug screening and therapeutic discovery.
Why Us?
Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.